MX2013007171A - Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. - Google Patents
Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.Info
- Publication number
- MX2013007171A MX2013007171A MX2013007171A MX2013007171A MX2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A MX 2013007171 A MX2013007171 A MX 2013007171A
- Authority
- MX
- Mexico
- Prior art keywords
- neoplasms
- treatment
- combination therapy
- inhibitor combination
- autophagy inducer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/062096 WO2012087336A1 (en) | 2010-12-23 | 2010-12-23 | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013007171A true MX2013007171A (es) | 2013-11-04 |
Family
ID=46314300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007171A MX2013007171A (es) | 2010-12-23 | 2010-12-23 | Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2655619A4 (pt) |
| JP (1) | JP2014507129A (pt) |
| KR (1) | KR20130132956A (pt) |
| CN (1) | CN103403161A (pt) |
| BR (1) | BR112013015891A2 (pt) |
| CA (1) | CA2821378A1 (pt) |
| MX (1) | MX2013007171A (pt) |
| RU (1) | RU2013134359A (pt) |
| WO (1) | WO2012087336A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6052540B2 (ja) * | 2012-12-21 | 2016-12-27 | 国立大学法人福井大学 | Ａｔｇ７変異体を用いたオートファジーの抑制方法 |
| JP6441232B2 (ja) | 2012-12-27 | 2018-12-19 | サノフイＳａｎｏｆｉ | 抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用 |
| KR101461916B1 (ko) | 2013-11-04 | 2014-11-19 | 현대자동차 주식회사 | 커플드 토션 빔 액슬 타입 현가장치 |
| JP7161760B2 (ja) * | 2017-02-03 | 2022-10-27 | 国立大学法人東北大学 | 複素環化合物 |
| WO2018226776A1 (en) * | 2017-06-08 | 2018-12-13 | The Penn State Research Foundation | Assay for monitoring autophagosome completion |
| EP3722419A4 (en) * | 2017-12-07 | 2021-12-08 | Pearl Kogyo Co., Ltd. | PROCESS FOR THE INTRODUCTION OF A SELECTED MOLECULE AND COMPOSITION CONTAINING AN INHIBITOR |
| CN108103194B (zh) * | 2017-12-27 | 2021-05-18 | 中国医学科学院药用植物研究所 | 一种抑制胃癌细胞mgc-803的靶点及其应用 |
| KR102095749B1 (ko) * | 2018-12-20 | 2020-04-01 | 충남대학교 산학협력단 | S6k1 유전자 발현 억제제 또는 s6k1 단백질 활성 억제제를 유효성분으로 포함하는, 미토콘드리아 내 자가포식 장애로 발생되는 질병의 예방 또는 치료용 조성물 |
| CN111593068B (zh) * | 2019-01-28 | 2023-10-17 | 广州溯原生物科技股份有限公司 | 新型基因治疗载体pIRES-Rsirt2/4-Tet-nap的制备方法及应用 |
| CN110592044B (zh) * | 2019-07-26 | 2021-06-22 | 中国农业科学院蔬菜花卉研究所 | 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006206478B2 (en) * | 2005-01-19 | 2012-04-12 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
| BRPI0615962A2 (pt) * | 2005-07-27 | 2011-05-31 | Univ Florida | uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional |
| UA95641C2 (en) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20100021420A1 (en) * | 2006-07-14 | 2010-01-28 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| KR101324390B1 (ko) * | 2009-06-05 | 2013-11-01 | 설대우 | 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 ｓｈＲＮＡ 발현 카세트 |
-
2010
- 2010-12-23 JP JP2013546098A patent/JP2014507129A/ja active Pending
- 2010-12-23 CA CA2821378A patent/CA2821378A1/en not_active Abandoned
- 2010-12-23 MX MX2013007171A patent/MX2013007171A/es not_active Application Discontinuation
- 2010-12-23 CN CN2010800712519A patent/CN103403161A/zh active Pending
- 2010-12-23 EP EP10861010.6A patent/EP2655619A4/en not_active Withdrawn
- 2010-12-23 RU RU2013134359/15A patent/RU2013134359A/ru not_active Application Discontinuation
- 2010-12-23 WO PCT/US2010/062096 patent/WO2012087336A1/en active Application Filing
- 2010-12-23 KR KR1020137019575A patent/KR20130132956A/ko not_active Application Discontinuation
- 2010-12-23 BR BR112013015891A patent/BR112013015891A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN103403161A (zh) | 2013-11-20 |
| WO2012087336A1 (en) | 2012-06-28 |
| JP2014507129A (ja) | 2014-03-27 |
| CA2821378A1 (en) | 2012-06-28 |
| KR20130132956A (ko) | 2013-12-05 |
| EP2655619A1 (en) | 2013-10-30 |
| BR112013015891A2 (pt) | 2016-10-04 |
| RU2013134359A (ru) | 2015-01-27 |
| EP2655619A4 (en) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013007171A (es) | Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. | |
| TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| PL2694485T3 (pl) | Kombinacja związku inhibitora akt i wemurafenibu do zastosowania w leczeniach terapeutycznych | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| MX340290B (es) | Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación. | |
| NZ587057A (en) | Method of treating prostate cancer with the gnrh antagonist degarelix | |
| CL2018000927A1 (es) | Terapia combinada para el tratamiento de neoplasias malignas | |
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
| MX2016005294A (es) | Metodos para tratar y prevenir enfermedad injerto contra huésped. | |
| MX2020005533A (es) | Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek. | |
| MX350463B (es) | Métodos de tratamiento del dolor. | |
| MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| IN2014DN10404A (pt) | ||
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| EP2584900A4 (en) | COMBINATION THERAPY WITH CRYOSURGERY AND IMIQUIMOD WITH LOW DOSE THICKNESS FOR THE TREATMENT OF ACTIVE KERATOSIS | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| MX2011007384A (es) | Terapias de combinacion para trastornos neoplásticos. | |
| WO2012129145A8 (en) | Nsclc combination therapy | |
| BR112012018906A2 (pt) | materiais e acessórios para a aplicação da terapia fotodinâmica antibacteriana | |
| TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |